Drug intelligence / Profile preview

Ruji formula

Development stage: Preclinical
Lead developer: Foshan Hospital of Traditional Chinese Medicine
Administration: Oral (assumed Based On Standard Tcm Practice)

Overview

Ruji formula is a traditional Chinese medicine (TCM) herbal compound used in the adjunctive treatment of breast cancer, particularly triple-negative breast cancer (TNBC). It has been studied for its effects on postoperative immune function and circulating tumor cells in patients with TNBC. Preclinical research suggests that Ruji formula may influence miRNA expression in breast cancer cell lines, potentially impacting tumor recurrence and metastasis. The exact composition of the herbal ingredients is not specified in available English-language sources, but it is administered as part of integrative therapy protocols alongside other TCM interventions such as shuowang moxibustion[1][6][8][10].

Other names: 乳积方

Beyond the preview

Go deeper on Ruji formula.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ruji formula.

Explore the full profile